Cargando…
Gemcitabine plus oxaliplatin for the treatment of leptomeningeal metastases of non-small cell lung cancer: A case report and review of the literature
A 62-year-old male presented with stage IV lung adenocarcinoma with leptomeningeal metastases (LM). Gemcitabine (1000 mg/m(2) i.v.) was administered on days 1 and 8 while oxaliplatin (100/m(2) i.v.) was administered on day 1 and repeated for 4 cycles every 3 weeks. Computerized tomography (CT) and c...
Autores principales: | BAI, CHONG, SHI, HUI, LIU, DAN, ZHU, TIANYI, HU, ZHENLI, LI, QIANG |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3678890/ https://www.ncbi.nlm.nih.gov/pubmed/23760544 http://dx.doi.org/10.3892/ol.2013.1263 |
Ejemplares similares
-
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
por: Cappuzzo, F, et al.
Publicado: (2005) -
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022) -
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
por: Ceccon, Garry, et al.
Publicado: (2020) -
Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin
por: Dias, Daniela, et al.
Publicado: (2023) -
Editorial: Brain and leptomeningeal metastases in lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2023)